

February 11, 2025

To, The General Manager, Department of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

COMPANY CODE : BAYERCROP SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: News Release - Unaudited Financial Results for the quarter ended on December 31, 2024.

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,

for Bayer CropScience Limited

**Bharati Shetty** Company Secretary & Compliance Officer (Membership No. ACS 24199)

Encl.: As above

Bayer CropScience Ltd. CIN: L24210MH1958PLC011173

Registered and Corporate Office: Bayer House Central Avenue Hiranandani Estate Thane (West) – 400 607 Maharashtra, India

Tel: +91 22 2531 1234 Fax: +91 22 2545 5063 www.bayer.in www.cropscience.bayer.com

# RESTRICTED



Bayer Group in India Communications Bayer House, Central Avenue Hiranandani Estate Thane (West) - 400607 Maharashtra, India www.bayer.in

### **News Release**

#### Quarterly Results

### Bayer CropScience Limited reports Q3 results for FY 2024-25

- Revenue from Operations of ₹ 10,569 million
- Profit Before Tax of ₹ 336 million

**Mumbai, February 11, 2025:** Bayer CropScience Limited (BSE: 506285) announced on Tuesday its unaudited results for the quarter and nine months ended December 31, 2024.

In the third quarter (Q3) of Financial Year (FY) 2024-25, Bayer CropScience Limited (BCSL) earned Revenue from Operations of ₹ 10,569 million, as compared to ₹ 9,549 million in the corresponding period of FY 2023-24. Profit Before Tax stood at ₹ 336 million, compared to ₹ 1,242 million in the corresponding period of FY 2023-24.

For the nine months ended December 31, 2024, BCSL reported Revenue from Operations of ₹ 44,257 million, compared to ₹ 43,117 million for the corresponding period in FY 2023-24. Profit Before Tax for the nine months ended December 31, 2024, stood at ₹ 5,395 million, compared to ₹ 8,360 million for the corresponding period in FY 2023-24.

Commenting on the quarterly performance, Simon Wiebusch, Vice Chairman, Managing Director and Chief Executive Officer, BCSL said, "In Q3, BCSL saw a 11% increase in Revenue from Operations, mainly driven by growth in our Corn business. We prioritized market share gains and launches of new hybrids. Improved reservoir levels compared to last year helped rice cultivation in the South, though growth and profit in our agrochemical business was tempered by reduced investments in the chilli crop. Overall, the current growing season shows good liquidation."

Simon Britsch, Whole-time Director (Executive) and Chief Financial Officer, BCSL said, "Continuing cost efficiency measures were offset by targeted investments in promotional activities as well as provisions for doubtful receivables, attributable to a challenging agricultural economy. We are actively engaged in recovery efforts."

We take this opportunity to welcome Vinit Jindal as Whole-Time Director designated as Executive Director and Chief Financial Officer, effective March 01, 2025, as part of a planned leadership transition. We also extend our gratitude to Simon Britsch for his successful efforts and strong commitment to the sustainable growth of BCSL during his tenure.

### About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims

to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

#### **Media Contact**

Snigdha Vishal Communications, Bayer CropScience Limited E-mail: snigdha.vishal@bayer.com

#### Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

# RESTRICTED